Gene Probes pp 43-59

Part of the Methods in Molecular Biology book series (MIMB, volume 179)

Evaluation of Alterations in the Tumor Suppressor Genes INK4A and INK4B in Human Bladder Tumors

  • Irene Orlow
  • Carlos Cordon-Cardo

Abstract

The progression through the cell cycle is monitored by positive and negative regulators. One family of negative regulators has been reported to act as cyclin-dependent kinase inhibitors (CKI) (1, 2, 3); and these, in turn, have been subdivided into two groups on the basis of sequence homology. The first CKI family includes p21Cip1 (4, 5, 6), p27Kip1 (7, 8, 9), and p57 Kip2 (10,11). The other CKI subgroup includes four members: p16INK4A/MTS1/CDKN2A (12,13), p15INK4B/MTS2/CDKN2B (14), p18INK4C (15), and p19INK4D (16). The INK4A and INK4B genes map to the short arm of chromosome 9 (9p21), where they are found in tandem spanning a region of approx 80 kilobases (kb) (Fig. 1). The INK4A and the INK4B genes encode for the p16 and the p15 proteins, respectively (12, 13, 14). These protein products form binary complexes exclusively with Cdk4 and Cdk6, inhibiting their function and, by doing so, inhibiting pRB phosphorylation during G1. Additional complexity results from the presence of a second INK4A product, termed p19ARF or p14ARF in humans (ARF is the acronym for alternative reading frame) (17, 18, 19, 20) (Fig. 1). The p19ARF blocks the mdm2-induced p53 degradation and transactivational silencing (21,22). The INK4A is altered in many cell lines and primary tumors (23, 24, 25, 26). Furthermore, germ line mutations of the INK4A gene are found on patients with familial melanoma and pancreatic adenocarcinoma (27, 28); and targeted deletion of the INK4A in murine models is associated with the development of spontaneous tumors (29,30).
Fig. 1.

Genomic organization of the INK4A and INK4B gene locus.

References

  1. 1.
    Sherr, C. J. (1996) Cancer cell cycles. Science 274, 1672–1677.PubMedCrossRefGoogle Scholar
  2. 2.
    Clurman, B. E. and Roberts, J. M. (1995) Cell cycle and cancer. J. Natl. Cancer Inst. 87, 1499–1501.PubMedCrossRefGoogle Scholar
  3. 3.
    Cordón-Cardó, C. (1995) Mutation of cell cycle regulators. Am. J. Pathol. 147, 545–559.PubMedGoogle Scholar
  4. 4.
    El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825.PubMedCrossRefGoogle Scholar
  5. 5.
    Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993) The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805–816.PubMedCrossRefGoogle Scholar
  6. 6.
    Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366, 701–704.PubMedCrossRefGoogle Scholar
  7. 7.
    Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., et al. (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8, 9–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Toyoshima, H. and Hunter, T. (1994) p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78, 67–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Ponce-Castañeda, V. M., Lee, M. H., Latres, E., Polyak, K., Lacombe, L., Montgomery, K., et al. (1995) p27 Kip1: chromosomal mapping to 12p12–12p13.1 and absence of mutations in human tumors. Cancer Res. 55,1211–1214.PubMedGoogle Scholar
  10. 10.
    Lee, M.-H, Reynisdóttir, I., and Massague, J. (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9, 639–649.PubMedCrossRefGoogle Scholar
  11. 11.
    Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A. (1995) p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitory family, is a candidate tumor suppressor gene. Genes Dev. 9, 650–662.PubMedCrossRefGoogle Scholar
  12. 12.
    Serrano, M., Hannon, G. J., and Beach, D. (1993) A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704–707.PubMedCrossRefGoogle Scholar
  13. 13.
    Kamb, A., Gruis, N. A., Weaver Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436–440.PubMedCrossRefGoogle Scholar
  14. 14.
    Hannon, G. J. and Beach, D. (1994) p15 INK4B is a potential effector of TGFβ-induced cell cycle arrest. Nature 371, 257–261.PubMedCrossRefGoogle Scholar
  15. 15.
    Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., and O’Keefe, C. L. (1994) Growth suppression by p18, a p16INK4/MTS1 and p14INK4B/MTS2a-related CDK6 inhibitor, correlates with wild-type pRB function. Genes Dev. 8, 2939–2952.PubMedCrossRefGoogle Scholar
  16. 16.
    Okuda, T., Hirai, H., Valentine, V. A., Shurtleff, S. A., Kidd, V. J., and Lahti, J. M. (1995) Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4D, an inhibitor of cyclin D-dependent kinases. Genomics 29, 623–630.PubMedCrossRefGoogle Scholar
  17. 17.
    Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993–1000.PubMedCrossRefGoogle Scholar
  18. 18.
    Duro, D., Bernard, O., Della Valle, V., Berger, R., and Larsen, C. J. (1995) A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11, 21–29.PubMedGoogle Scholar
  19. 19.
    Mao, L., Merlo, A., Bedi, G., Shapiro, G. I., Edwards, C. D., and Rollins, B. J. (1995) A novel p16INK4A transcript. Cancer Res. 55, 2995–2997.PubMedGoogle Scholar
  20. 20.
    Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., and Parry, D. (1995) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res. 55, 2988–2994.PubMedGoogle Scholar
  21. 21.
    Pomerantz, J., Schrieber-Agus, N., Liegoeis, N., Silverman, A., Alland, L., and Chin, L. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92, 713–723.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang, Y., Xiong, Y., and Yarbrough, W. G. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725–734.PubMedCrossRefGoogle Scholar
  23. 23.
    Jen, J., Harper, J. W., Bigner, S. H., Bigner, D. D., Papadopoulos, N., Markowitz, S., et al. (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353–6358.PubMedGoogle Scholar
  24. 24.
    Spruck, C. H. III, Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M. F., Gonzales, F., et al. (1994) p16 gene in uncultured tumours. Nature 370, 183–184.PubMedCrossRefGoogle Scholar
  25. 25.
    Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Frye, C., Eeles, R., Orlow, I., et al. (1995) Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol. 146, 1199–1206.PubMedGoogle Scholar
  26. 26.
    Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., et al. (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56, 3630–3633.PubMedGoogle Scholar
  27. 27.
    Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., Clark, W. H. Jr, et al. (1994) Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15–21.PubMedCrossRefGoogle Scholar
  28. 28.
    Goldstein, A. M., Fraser, M. C., Struewing, J. P., Hussussian, C. J., Ranade, K., Zametkin, D. P., et al. (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med. 333, 970–974.PubMedCrossRefGoogle Scholar
  29. 29.
    Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27–37.PubMedCrossRefGoogle Scholar
  30. 30.
    Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649–659.PubMedCrossRefGoogle Scholar
  31. 31.
    Orlow, I., Lianes, P., Lacombe, L., Dalbagni, G., Reuter, V. E., and Cordon-Cardo, C. (1994) Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res. 54, 2848–2851.PubMedGoogle Scholar
  32. 32.
    Orlow, I., Lacombe, L., Hannon, G. J., Serrano, M., Pellicer, I., Dalbagni, G., et al. (1995) Deletion of the p16 and p15 genes in human bladder tumors. J. Natl. Cancer Inst. 87, 1524–1529.PubMedCrossRefGoogle Scholar
  33. 33.
    Orlow, I., LaRue, H., Osman, I., Lacombe, L., Moore, L., Rabbani, F., et al. (1999) Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am. J. Pathol. 155, 105–113.PubMedCrossRefGoogle Scholar
  34. 34.
    Southern, E. M. (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98, 503–517.PubMedCrossRefGoogle Scholar
  35. 35.
    Zariwala, M., Liu, E., and Xiong, Y. (1996) Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15ink4b and p18ink4c in tumor derived cell lines and primary tumors. Oncogene 12, 451–455.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2002

Authors and Affiliations

  • Irene Orlow
    • 1
  • Carlos Cordon-Cardo
    • 2
  1. 1.Department of Epidemiology and BiostatisticsMemorial Sloan-Kettering Cancer Center
  2. 2.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew York

Personalised recommendations